Alterity Therapeutics Ltd
ATHE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131343
In the last 90 days, Alterity Therapeutics Ltd insiders filed 1 open-market purchase and 0 sales; 21 institutions reported holding it in 13F filings for Q2 2026, worth $2.12M in total; no superinvestor holds it.
Other share classesPRNAF
13F holders, Q2 2025
Institutional positions in Alterity Therapeutics Ltd as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −1 vs. Q1 2025
- Shares held
- 221.8K
- −19.9K (−8.2%) vs. Q1 2025
- Total value
- $906.9K
- +$73.1K (+8.8%) vs. Q1 2025
- New holders
- 2
- 1 more added
- Sold out
- 3
- 1 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ATHE on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 21 | $2.12M |
| Q1 2026 | 15 | $1.12M |
| Q4 2025 | 18 | $1.00M |
| Q3 2025 | 16 | $1.26M |
| Q2 2025 | 11 | $906.9K |
| Q1 2025 | 12 | $833.9K |
| Q4 2024 | 13 | $415.9K |
| Q3 2024 | 13 | $148.6K |
| Q2 2024 | 10 | $140.9K |
| Q1 2024 | 10 | $193.8K |
| Q4 2023 | 9 | $226.7K |
| Q3 2023 | 8 | $143.5K |
| Q2 2023 | 7 | $163.2K |
| Q1 2023 | 7 | $260.3K |
| Q4 2022 | 13 | $230.5K |
| Q3 2022 | 9 | $299.0K |
| Q2 2022 | 10 | $441.0K |
| Q1 2022 | 13 | $643.0K |
| Q4 2021 | 11 | $541.0K |
| Q3 2021 | 14 | $808.1K |
| Q2 2021 | 14 | $1.29M |
| Q1 2021 | 12 | $1.45M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Alterity Therapeutics Ltd; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Point72 Asset Management, L.P. | 131,431 | $537.3K | 0.00% | 00.0% | Unchanged |
| Morgan Stanley | 58,301 | $238.4K | 0.00% | +14,600+33.4% | Added |
| Greenleaf Trust | 17,000 | $69.5K | 0.00% | +17,000 | New |
| BNP Paribas Arbitrage, SA | 8,190 | $33.5K | 0.00% | −1,562−16.0% | Reduced |
| Twin Lakes Capital Management, LLC | 5,925 | $24.2K | 0.01% | 00.0% | Unchanged |
| EverSource Wealth Advisors, LLC | 628 | $2.57K | 0.00% | +628 | New |
| Advisor Group Holdings, Inc. | 181 | $740 | 0.00% | 00.0% | Unchanged |
| Rhumbline Advisers | 130 | $533 | 0.00% | 00.0% | Unchanged |
| Ronald Blue Trust, Inc. | 40 | $164 | 0.00% | 00.0% | Unchanged |
| Steward Partners Investment Advisory, LLC | 6 | $25 | 0.00% | 00.0% | Unchanged |
| Danske Bank A/S | 1 | $4 | 0.00% | 00.0% | Unchanged |
| HB Wealth Management, LLC | 0 | $0 | 0.00% | −37,483−100.0% | Sold out |
| UBS Group AG | 0 | $0 | 0.00% | −13,004−100.0% | Sold out |
| JPMorgan Chase & Co | 0 | $0 | 0.00% | −53−100.0% | Sold out |